After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...

CEO Christopher Viehbacher told investors at TD Cowen’s 46th Annual Healthcare Conference that the company is focused on ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Biogen (BIIB) has put fresh attention on its spinal muscular atrophy pipeline after sharing new Phase 1b salanersen data ...

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still ...

The company’s positioning frequently appears alongside broader movements.

Biogen raised its full-year earnings forecast Thursday as cost-cutting and the rollout of new products, including the closely watched Alzheimer’s drug Leqembi, helped make up for declining sales of ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.